Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.693
+0.015 (2.17%)
Nov 21, 2024, 4:00 PM EST - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
10.05M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aytu BioPharma | 79.76M |
Kiora Pharmaceuticals | 16.02M |
Dominari Holdings | 12.59M |
MSP Recovery | 10.73M |
T2 Biosystems | 7.68M |
Ensysce Biosciences | 4.42M |
Alterity Therapeutics | 2.68M |
FOXO Technologies | 155.00K |
IMNN News
- 13 days ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 14 days ago - IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 21 days ago - IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - GlobeNewsWire
- 22 days ago - IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 6 weeks ago - IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management - GlobeNewsWire
- 3 months ago - IMUNON to Host R&D Day on September 18th - GlobeNewsWire